Peripheral Transcriptome of Clinical High-Risk Psychosis Reflects Symptom Alteration and Helps Prognosis Prediction.

Weichen Song,Lihua Xu,Tianhong Zhang,Weidi Wang,Yingmei Fu,Qingqing Xu,Ruixue Yuan,Ailing Ning,Jijun Wang,Guan Ning Lin,Shunying Yu
DOI: https://doi.org/10.1111/pcn.13346
2022-01-01
Psychiatry and Clinical Neurosciences
Abstract:Aims Clinical high-risk psychosis (CHR-P) refers to a heterogeneous state where patients exhibit psychotic syndromes such as hallucination and delusion not reaching the diagnostic criteria, with the ability of selfreasoning and help-seeking partially maintained. These characteristics make CHR-P an ideal phase for the early treatment of schizophrenia. Researchers have made great efforts to study peripheral molecular markers with the advantages of feasibility and objectivity that could predict CHR-P outcomes, such as using proteome and metabolome with success. For RNA, studies such as Influence du Cannabis sur l’émergence de symptômes psychopathologiques des Adolescents et jeunes Adultes présentant un état mental à Risque (ICAAR) and the NAPLS (North American Prodrome Longitudinal Study) cohort have already shown that RNA and microRNA had significant alterations during CHR-P conversion to psychosis, suggesting that blood transcriptome had the potentiality of being used as a biomarker.
What problem does this paper attempt to address?